Santen Pharmaceutical Co., Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Santen Pharmaceutical Co., Ltd. generated cash of $72,649,000,000, which is more than the previous year. Cash used in financing activities reached the amount of -$34,031,000,000 last year. Net change in cash is therefore $36,679,000,000.
Cash Flow
| 2015 | 25.38B | -61.70B | 28.96B |
|---|---|---|---|
| 2016 | 22.52B | 37.05B | -24.06B |
| 2017 | 10.84B | -28.20B | -28.65B |
| 2018 | 42.84B | -8.25B | -17.63B |
| 2019 | 32.89B | -2.93B | -28.10B |
| 2020 | 39.94B | -5.17B | -12.72B |
| 2021 | 38.80B | -53.35B | -16.68B |
| 2022 | 46.04B | -35.16B | 5.55B |
| 2023 | 37.14B | -26.77B | -37.22B |
| 2024 | 72.64B | -6.14B | -34.03B |
SNPHY Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 57.90B | 83.01B | 62.88B | 91.43B | 70.79B | 69.28B | 52.28B | 99.79B | 65.92B | 72.39B |
Operating activities | ||||||||||
Net income | 26.64B | -14.98B | 27.18B | 6.64B | 21.71B | 31.94B | 35.26B | 23.05B | 53.37B | 24.03B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 18.17B | 17.24B | 17.05B | 16.76B | 16.57B | 10.96B | 10.89B | 9.88B | 9.33B | 6.95B |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 18.38B | -6.44B | -1.96B | -7.51B | -3.05B | -6.30B | 0 | -5.48B | 0 | -7.70B |
Inventories | -1.36B | -1.14B | 5.38B | -4.59B | -981M | -5B | -1.43B | -4.12B | -5.38B | -521M |
Accounts payable | -2.38B | 3.68B | 2.49B | 4.94B | 717M | 2.44B | 0 | -425M | 0 | 0 |
Cash generated by operating activities | 72.64B | 37.14B | 46.04B | 38.80B | 39.94B | 32.89B | 42.84B | 10.84B | 22.52B | 25.38B |
Investing activities | ||||||||||
Purchases Of Investments | -301M | -589M | -1.06B | -3.38B | -398M | -931M | -565M | -478M | -2.23B | -198M |
Investments In Property Plant And Equipment | -9.31B | -24.58B | -35.84B | -23.80B | -9.22B | -8.33B | -9.93B | -9.5B | -9.09B | -66.44B |
Acquisitions Net | -207M | -3.47B | -2.96B | -29.18B | -3.40B | 1.47B | -5.95B | -19.06B | -4.09B | -62.81B |
Cash generated by investing activities | -6.14B | -26.77B | -35.16B | -53.35B | -5.17B | -2.93B | -8.25B | -28.20B | 37.05B | -61.70B |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | -1.38B | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | -11.88B | -12.60B | -11.99B | -11.18B | -10.37B | -10.58B | -10.55B | -10.75B | -9.92B | -8.26B |
Repurchases of common stock | -16.96B | -26.00B | -12M | 0 | -22M | -14.12B | -1M | -12.38B | 0 | 0 |
Repayments of term debt | -2.11B | 4.35B | 20.46B | -3B | -500M | -3.53B | -8.31B | -6.52B | -15.13B | 37.03B |
Cash used in financing activities | -34.03B | -37.22B | 5.55B | -16.68B | -12.72B | -28.10B | -17.63B | -28.65B | -24.06B | 28.96B |
Net Change In Cash | 36.67B | -25.11B | 20.12B | -28.54B | 20.63B | 1.51B | 17.00B | -47.51B | 33.87B | -6.47B |
Cash at end of period | 94.58B | 57.90B | 83.01B | 62.88B | 91.43B | 70.79B | 69.28B | 52.28B | 99.79B | 65.92B |